Target Information

Target General Infomation
Target ID
T63986
Former ID
TTDC00339
Target Name
mRNA of kinesin spindle protein
Gene Name
KIF11
Synonyms
mRNA of KIF11; mRNA of Kinesin-like protein 1; mRNA of Kinesin-like protein KIF11; mRNA of Kinesin-like spindle protein HKSP; mRNA of Kinesin-related motor protein Eg5; mRNA of TR-interacting protein 5; mRNA of TRIP-5; mRNA of Thyroid receptor-interacting protein 5; KIF11
Target Type
Clinical Trial
Disease Hematological malignancies [ICD9: 200-209; ICD10: C81-C86]
Liver cancer [ICD9: 140-229, 155, 203.0; ICD10: C22]
Function
Motor protein required for establishing a bipolar spindle. Blocking of KIF11 prevents centrosome migration and arrest cells in mitosis with monoastral microtubule arrays.
BioChemical Class
Kinesin-like protein family
Target Validation
T37756
UniProt ID
P52732
Sequence
MASQPNSSAKKKEEKGKNIQVVVRCRPFNLAERKASAHSIVECDPVRKEVSVRTGGLADK
SSRKTYTFDMVFGASTKQIDVYRSVVCPILDEVIMGYNCTIFAYGQTGTGKTFTMEGERS
PNEEYTWEEDPLAGIIPRTLHQIFEKLTDNGTEFSVKVSLLEIYNEELFDLLNPSSDVSE
RLQMFDDPRNKRGVIIKGLEEITVHNKDEVYQILEKGAAKRTTAATLMNAYSSRSHSVFS
VTIHMKETTIDGEELVKIGKLNLVDLAGSENIGRSGAVDKRAREAGNINQSLLTLGRVIT
ALVERTPHVPYRESKLTRILQDSLGGRTRTSIIATISPASLNLEETLSTLEYAHRAKNIL
NKPEVNQKLTKKALIKEYTEEIERLKRDLAAAREKNGVYISEENFRVMSGKLTVQEEQIV
ELIEKIGAVEEELNRVTELFMDNKNELDQCKSDLQNKTQELETTQKHLQETKLQLVKEEY
ITSALESTEEKLHDAASKLLNTVEETTKDVSGLHSKLDRKKAVDQHNAEAQDIFGKNLNS
LFNNMEELIKDGSSKQKAMLEVHKTLFGNLLSSSVSALDTITTVALGSLTSIPENVSTHV
SQIFNMILKEQSLAAESKTVLQELINVLKTDLLSSLEMILSPTVVSILKINSQLKHIFKT
SLTVADKIEDQKKELDGFLSILCNNLHELQENTICSLVESQKQCGNLTEDLKTIKQTHSQ
ELCKLMNLWTERFCALEEKCENIQKPLSSVQENIQQKSKDIVNKMTFHSQKFCADSDGFS
QELRNFNQEGTKLVEESVKHSDKLNGNLEKISQETEQRCESLNTRTVYFSEQWVSSLNER
EQELHNLLEVVSQCCEASSSDITEKSDGRKAAHEKQHNIFLDQMTIDEDKLIAQNLELNE
TIKIGLTKLNCFLEQDLKLDIPTGTTPQRKSYLYPSTLVRTEPREHLLDQLKRKQPELLM
MLNCSENNKEETIPDVDVEEAVLGQYTEEPLSQEPSVDAGVDCSSIGGVPFFQHKKSHGK
DKENRGINTLERSKVEETTEHLVTKSRLPLRAQINL
Structure
1II6; 1Q0B; 1X88; 1YRS; 2FKY; 2FL2; 2FL6; 2FME; 2G1Q; 2GM1; 2IEH; 2PG2; 2Q2Y; 2Q2Z; 2UYI; 2UYM; 2WOG; 2X2R; 2X7C; 2X7D; 2X7E; 2XAE; 3CJO; 3HQD; 3K3B; 3K5E; 3KEN; 3L9H; 3ZCW; 4A1Z; 4A28; 4A50; 4A51; 4A5Y; 4AP0; 4AQV; 4AQW; 4AS7; 4B7B; 4BBG; 4BXN; 4CK5; 4CK6; 4CK7
Drugs and Mode of Action
Drug(s) ALN-VSP Drug Info Phase 1 Liver cancer [550232]
EMD-534085 Drug Info Phase 1 Hematological malignancies [548638]
Inhibitor (S)-dimethylenastron Drug Info [531008]
(S)-enastron Drug Info [531008]
1-(7-methyl-9H-carbazol-3-yl)ethanone Drug Info [530951]
1-(trifluoromethyl)-9H-carbazole Drug Info [530951]
1-tert-butyl-9H-carbazole Drug Info [530951]
11H-benzo[a]carbazole Drug Info [530951]
2,3,4,11-tetrahydro-1H-benzo[a]carbazole Drug Info [530951]
2-(difluoromethyl)-9H-carbazole Drug Info [530951]
2-(trifluoromethoxy)-9H-carbazole Drug Info [530951]
2-(trifluoromethyl)-9H-carbazole Drug Info [530951]
2-ethyl-9H-carbazole Drug Info [530951]
2-isopropyl-9H-carbazole Drug Info [530951]
2-methyl-6-(trifluoromethyl)-9H-carbazole Drug Info [530951]
2-methyl-9H-carbazole Drug Info [530951]
2-tert-butoxy-9H-carbazole Drug Info [530951]
2-tert-butyl-7-(trifluoromethyl)-9H-carbazole Drug Info [530951]
2-tert-butyl-9H-carbazole Drug Info [530951]
3-(trifluoromethyl)-9H-carbazole Drug Info [530951]
3-methyl-6-(trifluoromethyl)-9H-carbazole Drug Info [530951]
3-tert-butyl-9H-carbazole Drug Info [530951]
4'-(trifluoromethyl)-4-biphenylol Drug Info [529002]
4'-(trifluoromethyl)-4-biphenylsulfonamide Drug Info [529002]
4'-(trifluoromethyl)-4-biphenylyl carbamate Drug Info [529002]
4'-(trifluoromethyl)-4-biphenylyl sulfamate Drug Info [529002]
4'-trifluoromethyl-biphenyl-4-ylamine Drug Info [529002]
4-(trifluoromethyl)biphenyl Drug Info [529002]
6-fluoro-2-methyl-9H-carbazole Drug Info [530951]
7-tert-butyl-9H-carbazole-3-carboxylic acid Drug Info [530951]
9-methyl-2-(trifluoromethyl)-9H-carbazole Drug Info [530951]
9H-carbazole-2-carbaldehyde Drug Info [530951]
9H-carbazole-3-carbaldehyde Drug Info [530951]
Adociasulfate-2 Drug Info [528349]
EMD-534085 Drug Info [530716]
Methyl 7-tert-butyl-9H-carbazole-3-carboxylate Drug Info [530951]
Methyl 9H-carbazole-2-carboxylate Drug Info [530951]
Methyl[4'-(trifluoromethyl)-4-biphenylyl]amine Drug Info [529002]
N-(4'-bromo-3,3'-difluoro-4-biphenylyl)urea Drug Info [529002]
N-(4'-chloro-4-biphenylyl)methanesulfonamide Drug Info [529002]
N-(4'-isopropyl-4-biphenylyl)urea Drug Info [529002]
N-(4'-methyl-4-biphenylyl)urea Drug Info [529002]
N-(4'-t-butyl-4-biphenylyl)urea Drug Info [529002]
N-[3'-(trifluoromethyl)-4-biphenylyl]urea Drug Info [529002]
N-[4'-(ethylsulfonyl)-3-fluoro-4-biphenylyl]urea Drug Info [529002]
N-[4'-(trifluoromethyl)-4-biphenylyl]sulfamide Drug Info [529002]
N-[4'-(trifluoromethyl)-4-biphenylyl]thiourea Drug Info [529002]
N-[4'-(trifluoromethyl)-4-biphenylyl]urea Drug Info [529002]
N-[4-(1,3-benzodioxol-5-yl)phenyl]sulfamide Drug Info [529002]
N-{4'-[(trifluoromethyl)sulfonyl]-4-biphenyl}urea Drug Info [529002]
N-{4'-[(trifluoromethyl)thio]-4-biphenyl}urea Drug Info [529002]
SB-731489 Drug Info [529002]
Pathways
Reactome MHC class II antigen presentation
Kinesins
WikiPathways MHC class II antigen presentation
Kinesins
References
Ref 548638Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027260)
Ref 550232Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).
Ref 528349J Med Chem. 2006 Aug 10;49(16):4857-60.Inhibition of kinesin motor proteins by adociasulfate-2.
Ref 529002J Med Chem. 2007 Oct 4;50(20):4939-52. Epub 2007 Aug 29.Novel ATP-competitive kinesin spindle protein inhibitors.
Ref 530716Bioorg Med Chem Lett. 2010 Mar 1;20(5):1491-5. Epub 2010 Jan 25.The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5.
Ref 530951J Med Chem. 2010 Jul 8;53(13):5054-8.Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds.
Ref 531008J Med Chem. 2010 Aug 12;53(15):5676-83.Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
Ref 549665US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression.
Ref 549672US patent application no. 7,407,943, Antisense modulation of apolipoprotein B expression.
Ref 550232Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).
Ref 1587926URL: https://www.ebi.ac.uk/chembl/ The ChEMBL database in 2017

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.